Jasper Therapeutics Inc. (JSPR) Financial Statements (2024 and earlier)

Company Profile

Business Address 2200 BRIDGE PKWY SUITE #102
REDWOOD CITY, CA 94065
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments86,88738,25084,7017701,213
Cash and cash equivalents86,88738,25084,7017701,213
Receivables250118150  
Prepaid expense1,121 2,272152326
Other current assets6524621  
Other undisclosed current assets6153,117687  
Total current assets:88,93841,73187,8319221,539
Noncurrent Assets
Operating lease, right-of-use asset1,4671,8861,147  
Property, plant and equipment2,7273,5683,686  
Long-term investments and receivables    100,339100,155
Long-term investments    100,339100,155
Restricted cash and investments417417345  
Other noncurrent assets1,343759645  
Total noncurrent assets:5,9546,6305,823100,339100,155
TOTAL ASSETS:94,89248,36193,654101,261101,694
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:6,2333,5555,74326995
Taxes payable  16
Employee-related liabilities1,151  
Accounts payable4,1491,7683,919  
Accrued liabilities2,0841,787   
Other undisclosed accounts payable and accrued liabilities   67326979
Other liabilities  194585  
Other undisclosed current liabilities6,1413,3161,692 16
Total current liabilities:12,3747,0658,020269111
Noncurrent Liabilities
Long-term debt and lease obligation:   2,380  
Liabilities, other than long-term debt4,0785,1391,249  
Due to related parties 6  
Other liabilities2,2642,353643  
Operating lease, liability1,8142,7862,380  
Derivative instruments and hedges, liabilities   600  
Other undisclosed noncurrent liabilities  16812,48716,6303,500
Total noncurrent liabilities:4,0785,30716,11616,6303,500
Total liabilities:16,45212,37224,13616,8993,611
Temporary equity, carrying amount    79,36293,082
Equity
Equity, attributable to parent, including:78,44035,98969,5185,0005,000
Common stock144  
Additional paid in capital248,039141,120136,96412,0774,998
Retained earnings (accumulated deficit)(169,600)(105,135)(67,450)(7,077)2
Other undisclosed equity, attributable to parent    00
Other undisclosed equity     96,694
Total equity:78,44035,98969,5185,000101,694
TOTAL LIABILITIES AND EQUITY:94,89248,36193,654101,261198,387

Income Statement (P&L) ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Revenues
(Other Income)
4,39613,5116,196  
Cost of revenue
(Cost of Goods and Services Sold)
    (7) 
Gross profit:4,39613,5116,196(7) 
Operating expenses(68,861)(51,196)(36,833)(935) 
Other undisclosed operating income (loss)(4,396)(13,511)(6,196)7 
Operating loss:(68,861)(51,196)(36,833)(935) 
Nonoperating income5,199586 383 
Investment income, nonoperating5,199    
Other nonoperating income (expense) 586 383 
Loss from continuing operations before equity method investments, income taxes:(63,662)(50,610)(36,833)(552) 
Other undisclosed loss from continuing operations before income taxes    (5,890) 
Loss from continuing operations before income taxes:(63,662)(50,610)(36,833)(6,442) 
Income tax expense    (38) 
Loss from continuing operations:(63,662)(50,610)(36,833)(6,481) 
Loss before gain (loss) on sale of properties:(36,833)(6,481) 
Other undisclosed net income 88,3106,196  
Net income (loss):(63,662)37,700(30,637)(6,481) 
Other undisclosed net loss attributable to parent(803)(75,385)   
Net loss available to common stockholders, diluted:(64,465)(37,685)(30,637)(6,481) 

Comprehensive Income ($ in thousands)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
12/31/2019
Net income (loss):(63,662)37,700(30,637)(6,481) 
Comprehensive income (loss), net of tax, attributable to parent:(63,662)37,700(30,637)(6,481) 

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: